EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antifungal effects and potential mechanism of bortezomib in combination with fluconazole against Candida albicans

Yuting Wang, Bing Wang, Jinfeng Li, Shuqing Ma, Peng Liu, Zhitao Teng, Haijie Zou, Rinan Cong, Xiaojing Sui, Xiaohui Li, Yingjie Cui

Frontiers in Cellular and Infection Microbiology · 2026

DOI: 10.3389/fcimb.2026.1856948 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Yuting Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, Shandong, China. Hauptthemen laut MEDLINE: Candida albicans, Antifungal Agents, Fluconazole, Bortezomib. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical management of Candida albicans ( C. albicans ) infections presents considerable problems, intensified by the few therapeutic choices available for this disease. The increasing resistance to fluconazole (FLC) following its widespread clinical use underscores the need for novel therapeutic strategies. Drug repurposing represents a promising approach to expand the antifungal armamentarium, and bortezomib (BTZ), a proteasome inhibitor originally approved for multiple myeloma, has emerged as a candidate for this purpose. This work systematically assessed the synergistic effects of fluconazole (FLC) with bortezomib (BTZ) on the susceptibility of C. albicans , focusing specifically on the planktonic and biofilm development phases. The results exhibited a synergistic antifungal effect of BTZ and FLC against FLC-resistant C. albicans in planktonic cells. The minimal inhibitory concentration (MIC) of BTZ decreased from 64-128 µg/ml to 8 µg/ml, whereas the MIC of FLC reduced from >128 µg/ml to 0.25 µg/ml, resulting in a fractional inhibitory concentration index (FICI) of less than 0.5. For FLC-susceptible C. albicans strains, the medication combination exhibited an indifferent interaction, with FICI above 0.5. The combination exhibited synergistic effects against C. albicans during the early stages of biofilm formation (4 and 8 h). The sessile minimum inhibitory concentration (sMIC) of FLC significantly lowered from ≥128 µg/mL to 0.25 µg/mL, whereas the sMIC of BTZ diminished from ≥128 µg/mL to 8-16 µg/mL, with a FICI of less than 0.5, signifying significant synergy. Time-kill assays revealed a delayed but sustained inhibitory effect against planktonic cells (24–48 h), while CFU enumeration confirmed a concentration-dependent reduction in biofilm viability, with the higher concentration (0.25 + 16) maintaining efficacy through 24 h. In vivo , using the Galleria mellonella ( G. mellonella ) infection model, the FLC+BTZ combination significantly improved larval survival, reduced fungal burden, and alleviated tissue damage compared with FLC monotherapy. Mechanistic studies demonstrated that this synergistic effect was mediated by multiple mechanisms, including the suppression of hyphal growth, inhibition of efflux pump activity, and intracellular formation of reactive oxygen species (ROS). These findings highlight the potential of drug repurposing in combating antifungal resistance and provide mechanistic insights into overcoming C. albicans drug resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Candida albicansAntifungal AgentsFluconazoleBortezomibDrug SynergismMicrobial Sensitivity TestsBiofilmsDrug Resistance, FungalAnimalsCandidiasisReactive Oxygen Species

Stichwörter der Autor:innen

Candida albicansantifungal effectantifungal mechanismsbortezomibcombination therapyfluconazole

Substanzen

Antifungal AgentsFluconazoleBortezomibReactive Oxygen Species

Autor:innen und Institutionen

  • Department of Pharmacy, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, Shandong, China.
  • Clinical Laboratory Center, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, Shandong, China.
  • Department of Cardiovascular Medicine, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, Shandong, China.

Zitieren

APA

Wang, Y., Wang, B., Li, J., Ma, S., Liu, P., Teng, Z., Zou, H., Cong, R., Sui, X., Li, X., & Cui, Y. (2026). Antifungal effects and potential mechanism of bortezomib in combination with fluconazole against Candida albicans. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2026.1856948

Vancouver

Wang Y, Wang B, Li J, Ma S, Liu P, Teng Z, et al. Antifungal effects and potential mechanism of bortezomib in combination with fluconazole against Candida albicans. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2026.1856948

BibTeX
@article{Wang2026,
  author = {Wang, Yuting and Wang, Bing and Li, Jinfeng and Ma, Shuqing and Liu, Peng and Teng, Zhitao and Zou, Haijie and Cong, Rinan and Sui, Xiaojing and Li, Xiaohui and Cui, Yingjie},
  title = {Antifungal effects and potential mechanism of bortezomib in combination with fluconazole against Candida albicans},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2026},
  doi = {10.3389/fcimb.2026.1856948}
}
Kostenlos starten →